How Do We Want To Live?
I’m happy to announce the imminent publication of my new book “Wie wollen wir leben?”. It’s on biological reductionism, psychiatry, and the creation of our future.
Prescribing Psychotropic Drugs? Join us in May in Mannheim!
/0 Comments/in Education, Pharmacokinetics, Psychopharmacology, Therapeutic Drug Monitoring /by Gerhard GründerThe 14. Symposium of the task force Therapeutic Drug Monitoring of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) will be held between May 13 and 15, 2020, in Mannheim.
How do Psychotropic Drugs Work?
/0 Comments/in Psychedelics, Psychiatry, Psychopharmacology, Spirituality, Video /by Gerhard GründerA video of my talk given at the Insight Conference in Berlin on Psychedelic Science on September 6th, 2019.
An Interview on the Foundations of Psychiatry
/0 Comments/in Antidepressants, Antipsychotics, Psychedelics, Psychiatry, Psychopharmacology /by Gerhard GründerAn interview for DasGehirn.Info on our understanding of psychopharmacology and its further development, about humanism and the political responsibility of psychiatry.
A Lecture on News in Psychopharmacology
/0 Comments/in Antidepressants, Antipsychotics, Depression, Psychedelics, Psychopharmacology, Schizophrenia /by Gerhard GründerMy lecture on “Hot Topic: Psychopharmaka”, held in Mainz on March 15th, 2019, as part of the teaching event “Psychiatrie Update 2019”, was videotaped.
Insight 2019: Integrating Science and Practice of Psychedelic States
/1 Comment/in Psychedelics, Psychiatry, Psychopharmacology, Spirituality /by Gerhard GründerThe Insight Conference 2019 on “Integrating Science and Practice of Psychedelic States” will take place in Berlin from September 5 – 7, 2019.
FDA Approves Esketamine for Treatment-Resistant Depression, While US Suicide Rate Reaches Record High
/0 Comments/in Antidepressants, Depression, Psychopharmacology /by Gerhard GründerThe US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.
Esketamine for treatment-resistant depression submitted to FDA
/2 Comments/in Depression, Psychopharmacology /by Gerhard GründerJanssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.
A Lecture on the “Crisis in Psychopharmacology”
/0 Comments/in Education, Psychopharmacology, Video /by Gerhard GründerLecture on “The Crisis of Psychopharmacology” at the scientific colloquium of the Department of Psychiatry and Psychotherapy of the University of Rostock.
DGPPN Summer School “Psychopharmacology” 2018 in Berlin
/0 Comments/in Education, Psychopharmacology /by Gerhard GründerOn June 28 and 29, 2018, the Summer School “Psychopharmacology”, organized by the German Society for Psychiatry and Psychotherapy, Psychosomatics and Neuroscience (DGPPN), will be held in Berlin.